Cancer Currents: An NCI Cancer Research Blog
A blog featuring news and research updates from the National Cancer Institute.
-
The success of mRNA vaccines for COVID-19 could help accelerate research on using mRNA vaccine technology to treat cancer, including the development of personalized cancer vaccines.
-
Results from three clinical trials have found that CAR T cells may be superior to standard treatments for patients with B-cell NHL that has not responded to treatment (refractory) or has returned after treatment (relapsed).
-
For patients with recurrent ovarian cancer who meet strict criteria, additional surgery may improve survival, results from a large clinical trial show.
-
Companies that want to market e-cigarettes in the United States must now submit applications to the Food and Drug Administration (FDA). In this interview, Mitch Zeller, director of FDA’s Center for Tobacco Products, provides insights into FDA actions on e-cigarettes.
-
A program called ACCURE is showing promise toward reducing disparities among Black and White patients with breast and lung cancers. ACCURE involves system-wide changes at cancer centers to overcome structural and cultural barriers in patient care.
-
Clinical trial finds that ipilimumab (Yervoy) and nivolumab (Opdivo) combo is superior to a combination of the targeted therapies dabrafenib (Tafinlar) and trametinib (Mekinist) as the first treatment for metastatic BRAF-positive melanoma.
-
For older adults with advanced cancer, a geriatric assessment can help direct their treatment, a new study shows. In the study, patients whose care was guided by a geriatric assessment experienced fewer serious side effects and falls in their homes.
-
Cancer cells can shed a protein called DDR1 that helps collagen proteins create dense barriers around tumors. A study in mice showed these barriers can prevent immune cells from entering and killing tumors.
-
A new test could potentially be used to identify children treated for medulloblastoma who are at high risk of their cancer returning. The test detects evidence of remaining cancer in DNA shed from medulloblastoma tumor cells into cerebrospinal fluid.
-
Most breast cancer risk tools were developed with data mainly from White women and don’t work as well for Black women. A new tool that estimates risk for Black women may help identify those who might benefit from earlier screening, enabling earlier diagnosis and treatment.